Bellus Health Email Format

Biotechnology ResearchQuebec, Canada11-50 Employees

Bellus Health is a clinical-stage biotechnology company focused on developing therapies for chronic cough and other disorders triggered by hypersensitization. Its lead candidate, BLU-5937, targets P2X3 receptors—sensorial nerve channels implicated in nervous system sensitization—and is being developed for chronic cough and chronic pruritus. The company also investigates how P2X3 activation contributes to irritation and pain and whether inhibiting these receptors could help other afferent hypersensitization–related disorders.

Based in Laval, Quebec, Bellus Health operates within the biotechnology research industry, advancing a clinical program aimed at sensory nerve–driven conditions. With a relatively small to mid-sized team, the company targets patients affected by chronic cough and related hypersensitization disorders, seeking to address unmet medical needs in this area.

Sign up for free to view info

Company overview Employee directory